scholarly journals Bisphosphonates and Atypical Fractures of Femur

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Tero Yli-Kyyny
Keyword(s):  
Task Force ◽  
Case Reports ◽  
Term Treatment ◽  
Mineral Research ◽  
Task Force Report ◽  
Treatment Of Osteoporosis ◽  
Atypical Fractures ◽  
Long Term Treatment ◽  
American Society

Bisphosphonates are the most widely prescribed medicines for the treatment of osteoporosis and have generally been regarded as well-tolerated and safe drugs. Since 2005, there have been numerous case reports about atypical fractures of the femur linked to long-term treatment of osteoporosis with bisphosphonates. Some attempts to characterize pathophysiology and epidemiology of these fractures have been published as well. However, as the American Society for Bone and Mineral Research (ASBMR) concluded in their task force report, the subject warrants further studies.

scholarly journals PROLIA (DENOSUMAB): ANALYSIS OF RECENT PUBLICATIONS FROM THE AMERICAN SOCIETY FOR BONE AND MINERAL RESEARCH (ASMBR) MEETING 2013

2013 ◽  
Vol 16 (3) ◽  
pp. 41-42
Author(s):  
E A Pigarova
Keyword(s):  
Bone Resorption ◽  
Fracture Risk ◽  
Human Monoclonal Antibody ◽  
Term Treatment ◽  
Mineral Research ◽  
Long Term Treatment ◽  
American Society ◽  
Favorable Conditions

On October 4—7, 2013 Baltimore (USA) hosted the Annual Congress of the American Society for Bone and Mineral Research (ASMBR), during which many publications were devoted to denosumab, a human monoclonal antibody to the main pathogenic link of osteoporosis — RANK-ligand, which results in a dramatic suppression of bone resorption, creating favorable conditions for the restoration of bone and a marked reduction in fracture risk. Some of the papers presented at the Congress deserve special attention and are discussed in this publication. These studies add new colors to the overall picture of denosumab action, showing efficacy of long-term treatment to suppress bone resorption, increase BMD, reduce fracture risk, improvement in the quality of the cortical bone tissue, ultrastructuralpreservation of normal bone parameters.

scholarly journals MANAGEMENT OF ENDOCRINE DISEASE: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy

2018 ◽  
Vol 178 (3) ◽  
pp. R81-R87 ◽  
Author(s):  
Robert A Adler
Keyword(s):  
Osteoporotic Fracture ◽  
Femoral Fractures ◽  
Osteoporosis Treatment ◽  
Term Treatment ◽  
Atypical Femoral Fractures ◽  
Treatment Of Osteoporosis ◽  
Endocrine Disease ◽  
Long Term Treatment ◽  
Term Management

Modern osteoporosis treatment began in the mid-1990s with the approval of amino-bisphosphonates, anti-resorptive agents that have been shown to decrease osteoporotic fracture risk by about half. In 2005, the first cases of atypical femoral fractures (AFF), occurring in the shaft of the femur, were reported. Since then, more cases have been found, leading to great concern among patients and a dramatic decrease in bisphosphonate prescribing. The pathogenesis and incidence of AFF are reviewed herein. Management and an approach to prevention or early detection of AFF are also provided. Denosumab, a more recently approved anti-resorptive medication has also been associated with AFF. Long-term management of osteoporosis and prevention of fracture are challenging in light of this serious but uncommon side effect, yet with an aging population osteoporotic fracture is destined to increase in frequency.

Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research

2016 ◽  
Vol 31 (10) ◽  
pp. 1910-1910 ◽  
Author(s):  
Robert A Adler ◽  
Ghada El-Hajj Fuleihan ◽  
Douglas C Bauer ◽  
Pauline M Camacho ◽  
Bart L Clarke ◽  
...  
Keyword(s):  
Task Force ◽  
Bisphosphonate Treatment ◽  
Mineral Research ◽  
American Society

Long-Term Management of Generalized Pustular Psoriasis with Infliximab: Case Series

2008 ◽  
Vol 12 (4) ◽  
pp. 184-188 ◽  
Author(s):  
Shannon B. Routhouska ◽  
Pranav B. Sheth ◽  
Neil J. Korman
Keyword(s):  
Case Reports ◽  
Case Series ◽  
Term Treatment ◽  
Pustular Psoriasis ◽  
Short Term Treatment ◽  
Long Term Treatment ◽  
Generalized Pustular Psoriasis ◽  
Factor Α ◽  
Term Management

Background: Infliximab, a tumor necrosis factor α antagonist, has recently been shown to be successful for the short-term treatment of generalized pustular psoriasis (GPP) in multiple case reports. Objective: The goal of this case series was to assess the efficacy of the longer-term management of GPP with infliximab. Methods: Three patients with severe GPP were followed to assess the efficacy of long-term treatment with infliximab. Results: Infliximab therapy was more efficacious with infusion every 6 to 8 weeks in combination with methotrexate. Conclusion: Infliximab may be efficacious for some patients for the long-term management of GPP. Maintaining a strict infliximab infusion schedule and concomitant methotrexate therapy may decrease infusion reactions and increase efficacy.

scholarly journals American Society for Bone and Mineral Research‐Orthopaedic Research Society Joint Task Force Report on Cell‐Based Therapies

2019 ◽  
Vol 35 (1) ◽  
pp. 3-17 ◽  
Author(s):  
Regis J O'Keefe ◽  
Rocky S Tuan ◽  
Nancy E Lane ◽  
Hani A Awad ◽  
Frank Barry ◽  
...  
Keyword(s):  
Task Force ◽  
Research Society ◽  
Mineral Research ◽  
Task Force Report ◽  
Orthopaedic Research ◽  
Joint Task ◽  
Joint Task Force ◽  
American Society
Sign in / Sign up

Export Citation Format

Share Document